Home / News / DM2


MDF Publishes First-ever CDM and DM2 Clinical Care Recommendations

SAN FRANCISCO, CA (May 2, 2019): The Myotonic Dystrophy Foundation (MDF) is pleased to announce the publication of the first-ever Consensus-based Care Recommendations for Congenital and Childhood-onset Myotonic Dystrophy Type 1 and Myotonic Dystrophy Type 2.

Linking DM Molecular Events to Insulin Resistance and Muscle Atrophy

Defective insulin signaling activation may underlie skeletal muscle wasting in DM1 and DM2.

MDF Medical School Roadshow

MDF designed this volunteer initiative to educate the next generation of medical professionals about myotonic dystrophy in order to improve clinical care and shorten the diagnostic odyssey. We need you!

Sleep and Disordered Breathing in DM2

Disorders of sleep and breathing are well characterized for DM1, but what about DM2?

Cycling to Drive Awareness and Hope

It was more than five years ago when Jeremy Kleiber went to check on a friend who wasn’t answering his found. He discovered his friend’s body with the man’s three-year-old daughter on his chest, crying for him to wake up.

Review: What Have We Learned About RAN Translation?

A new review looks at the cross-disease evidence for RAN translation’s contributions to pathogenesis.

Status: Clinical Outcome Measures for DM2

Publication of a new systematic review provides insights into clinical outcome measures for DM2.

Human iPSC-Derived Neurons for DM2

Induced pluripotential stem cells (iPSCs) from DM2 provide new tools for CNS-focused mechanistic and translational studies.

Similar Molecular Mechanisms, But Divergent Phenotypes in DM1 and DM2—Why?

The RNA binding protein, rbFOX1, competes with MBNL in binding to CCUGexp, but not CUGexp repeats, and thereby mitigates DM2.

Important New Review Articles on DM

The review journal, Frontiers in Neurology, is publishing six new articles on myotonic dystrophy.


© Myotonic Dystrophy Foundation. All rights reserved.